Ohmeda's Revex will launch in late May/early June; color-coded for post-op or opioid overdose reversal.
Executive Summary
OHMEDA REVEX LAUNCH TO OCCUR IN LATE MAY/EARLY JUNE to anesthesiology and emergency medical professionals, the Liberty Corner, N.J.-based subsidiary of the British BOC Group announced April 27. FDA approved NDA 20-459 (nalmefene HCl injection) April 17 for the reversal of opioid drug effects, including postoperative respiratory depression, induced by either natural or synthetic opioids, and for the management of known or suspected opioid overdose ("The Pink Sheet" April 24, In Brief).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth